Trikafta (elexacaftor/tezacaftor/ivacaftor) - Vertex
Post-exercise hypoglycaemia in adults with cystic fibrosis compared to healthy control adults. (PubMed, J Clin Transl Endocrinol) - Sep 18, 2026 - "This study investigated the prevalence of post-exercise hypoglycaemia in adults with CF (pre- and post-commencement of elexacaftor/tezacaftor/ivacaftor (ETI)), compared to healthy controls...There was also no significant increase in the prevalence or duration of hypoglycaemia for people with CF with abnormal glucose tolerance when comparing the 48 h post-exercise period to the 48 h period with the least exercise. The absence of any increase in significant hypoglycaemia in the post-exercise period should be reassuring for people with CF who have abnormal glucose tolerance, whether prescribed ETI or not, and their clinicians." 
Journal • Cystic Fibrosis • Diabetes • Genetic Disorders • Hypoglycemia • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42750872
 
Alana Hayes; Helen Jo; Jessica Marouvo; Katrin Kosbab-Jackson; Molly Cocks; Nicole Taylor; Ruth Dentice; Samantha Nolan; Sheila Sivam; Simone Visser; Tiffany J Dwyer; Veronica Yozghatlian; Yuankai Gu
 
Sep 18, 2026
 
Prev Next